Beigene (ONC) Competitors

GSK (NYSE:GSK) and Beigene (NASDAQ:ONC) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation.

Which has better valuation and earnings, GSK or ONC?

GSK has higher revenue and earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$31.38B	2.27	$3.29B	$1.59	21.75
Beigene	$3.81B	5.97	-$881.71M	-$6.14	-37.52

Which has more volatility & risk, GSK or ONC?

GSK has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Beigene has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.

Do institutionals and insiders believe in GSK or ONC?

15.7% of GSK shares are held by institutional investors. Comparatively, 48.5% of Beigene shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 7.4% of Beigene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media refer more to GSK or ONC?

In the previous week, GSK had 16 more articles in the media than Beigene. MarketBeat recorded 29 mentions for GSK and 13 mentions for Beigene. Beigene's average media sentiment score of 0.53 beat GSK's score of 0.27 indicating that Beigene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	14 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	7 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beigene	0 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer GSK or ONC?

GSK presently has a consensus price target of $43.25, indicating a potential upside of 25.06%. Beigene has a consensus price target of $316.67, indicating a potential upside of 37.47%. Given Beigene's stronger consensus rating and higher possible upside, analysts clearly believe Beigene is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	2.60
Beigene	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is GSK or ONC more profitable?

GSK has a net margin of 8.13% compared to Beigene's net margin of -25.94%. GSK's return on equity of 48.59% beat Beigene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	8.13%	48.59%	11.11%
Beigene	-25.94%	-25.12%	-14.95%

Does the MarketBeat Community prefer GSK or ONC?

GSK received 817 more outperform votes than Beigene when rated by MarketBeat users. However, 62.50% of users gave Beigene an outperform vote while only 57.12% of users gave GSK an outperform vote.

Company	Underperform	Outperform
GSK	Outperform Votes 822 57.12%	Underperform Votes 617 42.88%
Beigene	Outperform Votes 5 62.50%	Underperform Votes 3 37.50%

Summary

GSK beats Beigene on 12 of the 19 factors compared between the two stocks.